BlockchainFX presale hits $6.28M with 90% APY and 35% bonus tokens, outshining Algorand price predictions as the best presale crypto 2025.BlockchainFX presale hits $6.28M with 90% APY and 35% bonus tokens, outshining Algorand price predictions as the best presale crypto 2025.

Crypto Presale Alert: BlockchainFX Surges Ahead With $6.28M Raised as Algorand Price Predictions Lag

trading-chart1234567 main

What if you had the chance to join Ethereum or Solana before they exploded? Millions were made in those early allocations, yet most people missed out. Today, BlockchainFX ($BFX) offers that same window of opportunity, only this time with more utility, more rewards, and an explosive presale that experts are calling the best token presale 2025.

BFX

Early access crypto presales like this rarely stay open for long. With a limited time presale offer, a presale bonus closing soon, and a code that grants you 35% more tokens before August ends, this is the last chance crypto presale that could turn early buyers into tomorrow’s success stories. Scarcity drives urgency — miss this entry, and you’ll be watching from the sidelines when BFX hits its post-launch growth.

Final call: Use AUG35 to maximize your presale rewards with 35% bonus tokens.

BlockchainFX ($BFX): Explosive Presale With 1000x Potential

BlockchainFX isn’t a meme or a trend. It’s a trading super app combining crypto, stocks, forex, and commodities, already trusted by over 10,000 daily users. Unlike many undervalued altcoin presales, this project has real revenue, audited security through CertiK, and full compliance.

The presale has already raised $6.28M from 6,786+ participants, with token prices climbing from $0.02 to $0.021 ahead of a confirmed $0.05 launch. Projections place $BFX between $0.10 and $0.25 shortly after launch, and analysts see a long-term target above $1. That’s why this is trending presale crypto and the best crypto to buy now.

Urgency is heightened by the AUG35 bonus code — giving you 35% extra tokens if you join before August ends. Add to that a $500,000 giveaway, 90% APY rewards, and upcoming CEX listings, and it becomes clear why this is the top crypto asset to lock into today.

Ethereum’s presale launched at $0.31 before reaching thousands. Early buyers became millionaires. BlockchainFX offers your second chance at the same life-changing ROI. Join before this presale allocation closes and secure your place now.

BFX

Join before this presale allocation closes and secure your place now.

Algorand (ALGO): A Success Story That Sparked Regret

Algorand is one of crypto’s best known ICO success stories. Launched in 2019 at just $0.10, it went on to secure major adoption and today trades at around $0.14. Analysts predict it could reach the $1 level by 2025, with long-term forecasts pointing even higher.

The regret is clear: those who joined Algorand’s ICO multiplied their money, while those who waited missed out. That story echoes across the market — early adopters win, latecomers lose. While Algorand remains a strong project, its presale window has long closed.

That’s why BlockchainFX matters. With its presale allocation live, exclusive bonus tokens, and explosive growth potential, it represents the same chance Algorand once gave — only this time, you still have time to act.

bfx

Comparison Table: Why BlockchainFX Is the Urgent Token Presale

ProjectLaunch YearICO PriceCurrent Price2025 PredictionLong-Term TargetCurrent Status
Algorand2019$0.10$0.14$1.00$3–$5Established, ICO missed
BlockchainFX2025$0.02Presale $0.021$0.10–$0.25$1+Presale live, bonus closing soon

Act now — BlockchainFX presale allocation is live. Use code AUG35 for 35% more tokens before August ends.

Conclusion: Your Last Chance to Join the Next Millionaire-Maker Presale

Algorand showed the world how powerful early entry can be. From a $0.10 ICO to long-term forecasts above $3, it rewarded those who acted early. But the best token presale 2025 is happening now with BlockchainFX. With 1000x potential, explosive presale growth, 90% APY staking, and a $500,000 giveaway, it is the top crypto to invest in 2025.

This is your second chance. Join BlockchainFX before the presale bonus closes, use code AUG35 for 35% extra tokens, and secure your allocation today.

Find Out More Information Here

Website: https://blockchainfx.com/ 

X: https://x.com/BlockchainFXcom

Telegram Chat: https://t.me/blockchainfx_chat

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23